Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 267

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 267
---
, and the license to patents is exclusive for purposes of developing and commercializing Licensed Products in the
Romeg U.S. Territory until July 1, 2027 and, thereafter, is co-exclusive with Granules Pharmaceuticals, Inc. for the Romeg U.S. Territory Royalty Term for such purposes. The Romeg U.S. Territory Royalty
Term begins on the Original Signing Date and ends on the later of (i) expiration of the last to expire of the patents that covers the manufacture or commercialization of the Licensed Products in the Romeg U.S. Territory or (ii) the tenth
anniversary of the Original Signing Date. With respect to the foregoing clause (3), the license to know-how patents (if any) is exclusive during the Romeg Ex-U.S.
Territory Royalty Term, but is otherwise non-exclusive. The “Romeg Ex-U.S. Territory Royalty Term” begins on the date of the amendment agreement and ends on
the tenth anniversary of such date.

As consideration for the license under the Romeg License Agreement, we agreed to pay Romeg
(1) an up-front payment of $2.0 million, (2) upon our achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0 million,
(3) certain royalties in the mid-single digit percentage, based on annual net sales of the Licensed Products attributable to sales of the Licensed Products occurring in the Romeg U.S. Territory during the
Romeg U.S. Territory Royalty Term, with a quarterly minimum royalty of $150,000, and (4) pursuant to the amendment thereto, (a) certain royalties in the low-single digit percentage, based on annual
net sales of the Licensed Products attributable to sales of License Products in the Romeg Ex-U.S. Territory during the Romeg Ex-U.S. Territory Royalty Term and
(b) a one-time, non-refundable, non-creditable payment of $700,000. Pursuant to the amendment agreement, we also transferred
to Romeg 779,371 shares of our Common Stock.

The Romeg License Agreement will remain in effect until it is terminated in accordance with
the terms thereof. We may terminate the Romeg License Agreement (1) upon written notice to Romeg, if we elect (or are required) to withdraw the Initial Licensed Product from the market as a result of serious adverse reactions from use of such
product, which termination will be